Literature DB >> 10567896

Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and bcl-2.

S Buglioni1, I D'Agnano, M Cosimelli, S Vasselli, C D'Angelo, M Tedesco, G Zupi, M Mottolese.   

Abstract

About 40% of patients with colorectal carcinoma will develop local or distant tumour recurrences. Integrated analyses of bio-pathological markers, predictive of tumour aggressiveness, may offer a more rational approach to planning adjuvant therapy. To this end, we analysed the correlation between p53 accumulation, Bcl-2 expression, DNA ploidy, cell proliferation and conventional clinico-pathological parameters by testing the prognostic significance of these variables in a series of 171 colorectal carcinoma patients with long-term follow-up. The relationships among the various bio-pathological parameters, analysed by multiple correspondence analysis, showed 2 different clinico-biological profiles. The first, characterised by p53 negativity, Bcl-2 positivity, diploidy, low percentage of cells in S-phase (%S-phase), a low Ki-67 score, is associated with Dukes' A-B stage, well differentiated tumours and lack of relapse. The second, defined by p53 positivity, Bcl-2 negativity, aneuploidy, high %S-phase and elevated Ki-67 score, correlates with Dukes' C-D stage, poorly differentiated tumours and presence of relapse. When these parameters were examined according to Kaplan-Meier's method, significantly shorter disease-free (DFS) and overall survival (OS) were also observed in patients bearing p53 positive and Bcl-2 negative tumours, in Dukes' B stage. In multivariate analysis, p53 accumulation and Bcl-2 expression emerged as independent predictors of a worse and better clinical outcome, respectively. Our results indicate that, in colorectal adenocarcinomas, a biological profile, based on the combined evaluation of p53 and Bcl-2, may be useful for identifying high risk patients to be enrolled in an adjuvant setting, mainly in an early stage of the disease. Int. J. Cancer (Pred. Oncol.) 84:545-552, 1999. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10567896     DOI: 10.1002/(sici)1097-0215(19991222)84:6<545::aid-ijc1>3.0.co;2-2

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  22 in total

Review 1.  Development and progression of colorectal neoplasia.

Authors:  Upender Manne; Chandrakumar Shanmugam; Venkat R Katkoori; Harvey L Bumpers; William E Grizzle
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

2.  c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings.

Authors:  A Biroccio; B Benassi; I D'Agnano; C D'Angelo; S Buglioni; M Mottolese; A Ricciotti; G Citro; M Cosimelli; R G Ramsay; B Calabretta; G Zupi
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

3.  Clinical significance of molecular expression profiles of Hürthle cell tumors of the thyroid gland analyzed via tissue microarrays.

Authors:  Axel Hoos; Alexander Stojadinovic; Bhuvanesh Singh; Maria E Dudas; Denis H Y Leung; Ashok R Shaha; Jatin P Shah; Murray F Brennan; Carlos Cordon-Cardo; Ronald Ghossein
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

Review 4.  [Current status of the prognostic value of molecular markers in patients with colorectal cancer and the prediction of response to adjuvant therapy].

Authors:  Jose M Fernández-Cebrián; Peter Vorwald Kuborn; Mar Pardo de Lama; Alfonso Sanjuanbenito Dehesa; Manuel Nevado Santos; Pedro A Pacheco Martínez; Beatriz Fernández-Escudero
Journal:  Clin Transl Oncol       Date:  2005-04       Impact factor: 3.405

5.  Impact of BCL2 polymorphisms on survival in transitional cell carcinoma of the bladder.

Authors:  Jochen Hess; Patrick Stelmach; Andreas Eisenhardt; Herbert Rübben; Henning Reis; Kurt Werner Schmid; Hagen Sjard Bachmann
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-17       Impact factor: 4.553

Review 6.  [Clinical, pathological and molecular prognostic factors in colorectal carcinomas].

Authors:  S E Baldus
Journal:  Pathologe       Date:  2003-01-21       Impact factor: 1.011

7.  Correspondence analysis is a useful tool to uncover the relationships among categorical variables.

Authors:  Nadia Sourial; Christina Wolfson; Bin Zhu; Jacqueline Quail; John Fletcher; Sathya Karunananthan; Karen Bandeen-Roche; François Béland; Howard Bergman
Journal:  J Clin Epidemiol       Date:  2009-11-06       Impact factor: 6.437

8.  Prognostic significance and correlation with survival of bcl-2 and TGF-beta RII in colon cancer.

Authors:  Gregory Kouraklis; John Kakisis; Stamatios Theoharis; Antonia Tzonou; Andromachi Glinavou; John Raftopoulos; Gabriel Karatzas
Journal:  Dig Dis Sci       Date:  2003-12       Impact factor: 3.199

Review 9.  Segmental distribution of some common molecular markers for colorectal cancer (CRC): influencing factors and potential implications.

Authors:  Petros Christakis Papagiorgis
Journal:  Tumour Biol       Date:  2016-02-03

10.  A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study.

Authors:  Flavia Novelli; Michele Milella; Elisa Melucci; Anna Di Benedetto; Isabella Sperduti; Raffaele Perrone-Donnorso; Letizia Perracchio; Irene Venturo; Cecilia Nisticò; Alessandra Fabi; Simonetta Buglioni; Pier Giorgio Natali; Marcella Mottolese
Journal:  Breast Cancer Res       Date:  2008-09-04       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.